Abstract
Beta cell function in type 1 diabetes is commonly assessed as the average plasma C-peptide concentration over 2 h following a mixed-meal test (CPAVE). Monitoring of disease progression and response to disease-modifying therapy would benefit from a simpler, more convenient and less costly measure. Therefore, we determined whether CPAVE could be reliably estimated from routine clinical variables. Clinical and fasting biochemical data from eight randomised therapy trials involving participants with recently diagnosed type 1 diabetes were used to develop and validate linear models to estimate CPAVE and to test their accuracy in estimating loss of beta cell function and response to immune therapy. A model based on disease duration, BMI, insulin dose, HbA1c, fasting plasma C-peptide and fasting plasma glucose most accurately estimated loss of beta cell function (area under the receiver operating characteristic curve [AUROC] 0.89 [95% CI 0.87, 0.92]) and was superior to the commonly used insulin-dose-adjusted HbA1c (IDAA1c) measure (AUROC 0.72 [95% CI 0.68, 0.76]). Model-estimated CPAVE (CPEST) reliably identified treatment effects in randomised trials. CPEST, compared with CPAVE, required only a modest (up to 17%) increase in sample ...Continue Reading
References
Dec 1, 1981·The Journal of Clinical Investigation·R N BergmanC Cobelli
Mar 1, 1995·Diabetic Medicine : a Journal of the British Diabetic Association·E MobergU Adamson
May 28, 2005·Diabetes·Kevan C HeroldJeffrey A Bluestone
Nov 15, 2007·Diabetes Care·Jay M SosenkoUNKNOWN Diabetes Prevention Trial-Type 1 Study Group
Jul 17, 2008·Diabetes Care·Carla J GreenbaumUNKNOWN European C-Peptide Trial Study Group
May 14, 2009·Diabetes Care·Henrik B MortensenUNKNOWN Hvidoere Study Group on Childhood Diabetes
Nov 27, 2009·The New England Journal of Medicine·Mark D PescovitzUNKNOWN Type 1 Diabetes TrialNet Anti-CD20 Study Group
Jan 14, 2010·Diabetes Care·Peter A GottliebUNKNOWN Type 1 Diabetes TrialNet MMF/DZB Study Group
Jul 1, 2011·Lancet·Diane K WherrettUNKNOWN Type 1 Diabetes TrialNet GAD Study Group
Jul 2, 2011·Lancet·Nicole SherryUNKNOWN Protégé Trial Investigators
Jul 2, 2011·Lancet·Tihamer OrbanUNKNOWN Type 1 Diabetes TrialNet Abatacept Study Group
Apr 27, 2012·The New England Journal of Medicine·John C Pickup
Jun 13, 2012·Diabetes·Carla J GreenbaumUNKNOWN Type 1 Diabetes TrialNet Study Group
Sep 22, 2012·The Journal of Clinical Endocrinology and Metabolism·Roy W BeckUNKNOWN T1D Exchange Clinic Network
Dec 13, 2012·Diabetic Medicine : a Journal of the British Diabetic Association·J S Skyler
Apr 9, 2013·Lancet·Antoinette MoranUNKNOWN AIDA Study Group
Jul 3, 2013·Diabetes Care·Jay M SosenkoUNKNOWN Diabetes Prevention Trial-Type 1 Study Group
Jul 10, 2013·Diabetes·Kevan C HeroldUNKNOWN AbATE Study Team
Oct 15, 2013·Diabetes, Obesity & Metabolism·A BarkerP Pozzilli
Mar 14, 2014·The Lancet. Diabetes & Endocrinology·Mark R RigbyUNKNOWN T1DAL Study Team
Mar 14, 2014·The Lancet. Diabetes & Endocrinology·Stephen E GitelmanUNKNOWN START Study Team
Oct 8, 2014·Pediatric Diabetes·Marie Louise C Max AndersenHenrik B Mortensen
Sep 26, 2015·Diabetes Care·Diane K WherrettUNKNOWN Type 1 Diabetes TrialNet Study Group
Nov 5, 2016·Diabetes/metabolism Research and Reviews·Brian N BundyUNKNOWN Type 1 Diabetes TrialNet Study Group
Jul 17, 2016·Diabetes Care·Wei HaoUNKNOWN Type 1 Diabetes TrialNet Study Group
Nov 25, 2017·Pediatric Diabetes·Jay M SosenkoJerry P Palmer
Citations
Nov 6, 2018·Diabetologia·Flemming Pociot
Dec 18, 2018·Pediatric Diabetes·Kerry BuchananMark Harris
Jun 12, 2020·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Bas S UitbeijerseEelco J P de Koning
Sep 18, 2020·Acta Diabetologica·Joanna WangUNKNOWN ImMaDiab Study Group
Aug 28, 2020·Diabetes·Raffaella BuzzettiRichard David Leslie
Jan 27, 2020·Diabetologia·John M WentworthLeonard C Harrison
Aug 14, 2020·F1000Research·Sandra Lord, Carla J Greenbaum
Aug 3, 2021·Diabetologia·Naiara G BediagaJohn M Wentworth